Showing 5361-5370 of 8729 results for "".
- TikTok Trend Watch: Is Beer Tanning Really a Thing?https://practicaldermatology.com/news/tik-tok-trend-watch-is-beer-tanning-really-a-thing/2461976/TikTok is where many trends and DIY challenges get started, and skincare is one of the more popular categories for this content, for better or sometimes for worse. Take beer tanning, for example. Tik Tokkers are claiming that pouring beer on skin will activate melanin for a better
- L'Oréal's SkinCeuticals USA Appoints Angela Hildebrand as General Managerhttps://practicaldermatology.com/news/loreals-skinceuticals-usa-appoints-angela-hildebrand-as-general-manager/2461975/Angela Hildebrand is SkinCeuticals’ new General Manager and Amy Sloan is the Senior Vice President of Business Strategy and Growth. "With their collective knowledge, expertise, and dedication to excellence, Angela and Amy's leadership are poised to tak
- Are Wealthy People at Higher Risk for Skin Cancer?https://practicaldermatology.com/news/are-wealthy-people-are-more-prone-to-skin-cancer/2461972/Wealthier people are at greater risk for melanoma, according to new research in Cancers. “A higher socio-economic status is known to be associated with more vacations in sunny climates and recreational tanning, which likely ultimately drives melanoma incidence in this pop
- Study Links Gut Microbiome and Eczema in Infancyhttps://practicaldermatology.com/news/study-links-gut-microbiome-and-eczema-in-infancy/2461971/New research has revealed associations between the gut microbiome and eczema in infancy and has established the basis for the potential prevention and treatment of eczema via modulation of the gut microbiota. The study was
- AbbVie Awards 45 Scholarships to U.S. Students Living With Psoriasis, Eczema, and Other Chronic, Immune-Mediated Diseaseshttps://practicaldermatology.com/news/abbvie-awards-45-scholarships-to-us-students-living-with-psoriasis-eczema-and-other-chronic-immune-mediated-diseases/2461970/AbbVie announced the 2023-2024 class of
- FDA Clears Sofwave’s SUPERB Technology for Treating Acne Scarshttps://practicaldermatology.com/news/fda-clears-sofwaves-superb-technology-for-treating-acne-scars/2461969/The U.S. Food and Drug Administration (FDA) has cleared Sofwave’s SUPERB technology for treating acne scars. “Gaining FDA clearance to market SUPERB for the treatment of acne scarring not only paves the way to positively impact patients seeking improved appearances
- Tik Tok Trend Watch: Cyanide as a Potential Acne Cure?https://practicaldermatology.com/news/tik-tok-trend-watch-cyanide-as-a-potential-acne-cure/2461968/Tik Tok is where many trends and DIY challenges get started, and skin care one of the more popular categories for this content. The latest -- a viral video of a woman claiming that she has been 'secretly' feeding her boyfriend seeds containing cyanide (yes, that cyani
- Time Matters When Saving Skin During FLASH Radiotherapyhttps://practicaldermatology.com/news/time-matters-when-saving-skin-during-flash-radiotherapy/2461966/Multiple beams and intervals in delivery during FLASH proton therapy treatment may reduce skin-saving effects in preclinical models, according to a study in the International Journal of Radiation
- Christopher G. Bunick, MD, PhD, Receives the American Acne and Rosacea Society's 2023 Research Scholar Awardhttps://practicaldermatology.com/news/christopher-g-bunick-md-phd-receives-american-acne-and-rosacea-society-announces-2023-research-scholar-award/2461962/Christopher G. Bunick, MD, PhD, has received The American Acne and Rosacea Society’s (AARS) 2023 Research Scholar Award. Dr. Bunick is an Associate Professor of Dermatology at Yale University School of Medicine and a member of the Practical Dermatology magazine editorial board.</
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval cove